Trisalus Life Sciences (TLSI) Registration Filing summary

Company overview and business model

• Focuses on oncology, integrating innovative delivery technology with standard-of-care therapies and investigational immunotherapeutic nelitolimod for solid tumors.

• Technology addresses high intratumoral pressure and off-target delivery, aiming to improve therapeutic response and patient outcomes.

• Principal executive offices in Westminster, Colorado; incorporated in Delaware.

Financial performance and metrics

• No material adverse change in assets, business, or financial condition since December 31, 2023, except for ordinary course expenditures.

• Total purchase price for the private placement was approximately $1.0 million for 251,885 shares at $3.97 per share.

• As of March 31, 2025, 32,272,462 shares of common stock were outstanding.

Use of proceeds and capital allocation

• Will not receive any proceeds from the resale of shares by selling stockholders; all proceeds go to selling stockholders.

• Will bear all registration-related expenses; selling stockholders bear commissions and discounts.